相关实验视频

Updated: Jun 13, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

适应型冰淋对接受化疗的癌症患者营养状况和口腔粘膜炎的影响:随机对照试验的协议研究

Betina Fernanda Dambrós¹, Rafaela Alexia Kobus¹, Rafaela Caetano Horta de Lima¹

¹Post-Graduate Program in Nutrition, Department of Nutrition, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.

Clinical nutrition ESPEN

|January 25, 2025

概括

这项研究调查了适应型冰淋对血液癌或头癌的化疗患者的影响. 冰淋旨在改善营养状况并减少副作用,提供一种新的支持疗法.

科学领域:

在瘤学瘤学.
营养科学营养科学
临床试验设计临床试验设计

背景情况:

化学疗法用于血液和头癌症往往会导致不良事件影响营养和生活质量.
炎症和氧化应激与化疗引起的副作用有关.
一种适应的冰淋,富含蛋白质和纤维,脂肪减少,没有常见的过敏原,已被开发为化学疗法期间可能耐受良好的食物.

研究的目的:

为了评估特殊配方的冰淋在化疗期间作为营养干预措施的有效性.
评估这种干预措施对癌症患者的营养状况,口腔粘膜炎和生活质量的影响.
探索对食物消费,炎症标志物和味道变化的影响.

主要方法:

将实施一个两阶段随机临床试验协议.
参与者将每天获得120克适应型冰淋,持续21天 (第一阶段) 或63天 (第二阶段).
分层随机化将52名参与者 (26人/组) 分配到对照或干预组,监测营养状况和口腔粘膜炎作为主要结局.

主要成果:

数据收集方法是基于文献的,并对目标人群进行了验证.
这项研究旨在提供有关癌症治疗期间营养支持的相关信息.
结果将解决科学文献中关于这种特定营养干预措施的空白.

结论:

这项研究方案旨在提供有关向营养支持在癌症治疗中的作用的重要见解.
这些发现将为科学理解如何管理化疗副作用提供有价值的数据,无论是积极的还是消极的.
这项研究解决了最近系统性审查中发现的明显的科学差距.

关键词:

头癌是头部和部的癌症.血液学的新生体.营养干预措施营养干预措施协议研究研究协议研究随机临床试验随机临床试验

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...